Eli Lilly and Company (LLY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $922.50. It has a SharesGrow Score of 86/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of LLY = $919.68 (-0.3% from the current price, the stock appears fairly valued). Analyst consensus target is LLY = $1,244 (+34.8% upside).
Valuation: LLY trades at a trailing Price-to-Earnings (P/E) of 41.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.88.
Financials: revenue is $65.2B, +32.1%/yr average growth. Net income is $20.6B, growing at +60.3%/yr. Net profit margin is 31.7% (strong). Gross margin is 83.8% (+7 pp trend).
Balance sheet: total debt is $42.5B against $26.5B equity (Debt-to-Equity (D/E) ratio 1.6, leveraged). Current ratio is 1.58 (strong liquidity). Debt-to-assets is 37.8%. Total assets: $112.5B.
Analyst outlook: 33 / 45 analysts rate LLY as buy (73%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 47/100 (Partial), Growth 100/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 100/100 (Pass), Future 85/100 (Pass), Income 100/100 (Pass).
